These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31840356)

  • 1. EHL-FIX in haemophilia B carriers with FIX deficiency.
    Marlière C; Maindiaux L; Lambert C; Hermans C
    Haemophilia; 2020 Mar; 26(2):e38-e40. PubMed ID: 31840356
    [No Abstract]   [Full Text] [Related]  

  • 2. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
    van Galen KP; Engelen ET; Mauser-Bunschoten EP; van Es RJ; Schutgens RE
    Cochrane Database Syst Rev; 2015 Dec; (12):CD011385. PubMed ID: 26704192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of second-degree burn induced by dry ice in a Christmas disease patient.
    Troccola A; Maruccia M; Zampieri AE; Dessy LA
    Burns; 2010 Sep; 36(6):e115-8. PubMed ID: 20494523
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
    Wang C; Young G
    Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prophylaxis in haemophilia B. Prevention of bleeds and FIX consumption].
    Siegmund B; Richter H; Pollmann H
    Hamostaseologie; 2010 Nov; 30 Suppl 1():S35-8. PubMed ID: 21042666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.
    Iorio A; Fischer K; Blanchette V; Rangarajan S; Young G; Morfini M;
    Thromb Haemost; 2017 Jun; 117(6):1023-1030. PubMed ID: 28357444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B.
    Rampotas A; Desborough MJR; Raza-Burton S; Taylor S; Wilkinson A; Hall GW; Shapiro S; Curry N
    Haemophilia; 2020 Mar; 26(2):278-281. PubMed ID: 32083769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current status of prophylactic replacement therapy in children and adults with haemophilia.
    Ljung R; Gretenkort Andersson N
    Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of odontogenic large cysts in haemophiliac patients.
    Cakr O; Kazancoğlu HO; Ak G; Zülfikar B
    Blood Coagul Fibrinolysis; 2012 Apr; 23(3):253-4. PubMed ID: 22460824
    [No Abstract]   [Full Text] [Related]  

  • 11. How we treat: patients with haemophilia undergoing screening colonoscopy.
    Fogarty PF; Kouides P
    Haemophilia; 2010 Mar; 16(2):363-5. PubMed ID: 19845773
    [No Abstract]   [Full Text] [Related]  

  • 12. Haemophilia B: Where are we now and what does the future hold?
    Dolan G; Benson G; Duffy A; Hermans C; Jiménez-Yuste V; Lambert T; Ljung R; Morfini M; Zupančić Šalek S
    Blood Rev; 2018 Jan; 32(1):52-60. PubMed ID: 28826659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single centre experience in circumcision of haemophilia patients: Izmir protocol.
    Yilmaz D; Akin M; Ay Y; Balkan C; Celik A; Ergün O; Kavakli K
    Haemophilia; 2010 Nov; 16(6):888-91. PubMed ID: 20491959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemophilia A/B carriers: haemorrhagic burden of disease and open issues.
    Pasca S; Zanon E
    Blood Transfus; 2020 Nov; 18(6):496-497. PubMed ID: 32955424
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of third molar removal with a single dose of recombinant Factor IX (BeneFIX) and local measures in severe haemophilia B.
    Hewson ID; Makhmaloaf P
    Aust Dent J; 2010 Sep; 55(3):322-4. PubMed ID: 20887522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The management of hemophilia patients with inhibitors.
    Nilsson IM
    Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
    [No Abstract]   [Full Text] [Related]  

  • 17. Current issues in prophylactic therapy for persons with hemophilia.
    Dunn AL; Abshire TC
    Acta Haematol; 2006; 115(3-4):162-71. PubMed ID: 16549891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.
    Powell J; Shapiro A; Ragni M; Negrier C; Windyga J; Ozelo M; Pasi J; Baker R; Potts J; Li S; Mei B; Pierce GF; Robinson B
    Br J Haematol; 2015 Jan; 168(1):113-23. PubMed ID: 25209873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: Evidence from clinical trials and real-world practice.
    Mancuso ME; Oldenburg J; Boggio L; Kenet G; Chan A; Altisent C; Seifert W; Santagostino E
    Haemophilia; 2020 Jul; 26(4):637-642. PubMed ID: 32542961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B.
    Hoots WK; Leissinger C; Stabler S; Schwartz BA; White G; Dasani H; Massion C; Negrier C; Schindel F; Schulman S
    Haemophilia; 2003 Mar; 9(2):164-72. PubMed ID: 12614367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.